Clinical Trial Detail

NCT ID NCT04349267
Title Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

lung non-small cell carcinoma

renal cell carcinoma

head and neck squamous cell carcinoma

Therapies

BMS-986315 + Cetuximab

BMS-986315

BMS-986315 + Nivolumab

Age Groups: adult senior

No variant requirements are available.